Equitable Holdings, Inc. (EQH), a major player in life insurance, annuities, and asset management, has shown a rollercoaster ride over the past decade that’s mirrored the ups and downs of the financial services sector. Spun off from AXA Equitable in a blockbuster 2018 IPO—one of the largest life insurance demutualizations ever—EQH navigated the COVID-19 market crash in 2020, which hammered its stock to lows around $10 per share, before staging a solid recovery fueled by rising interest rates and strong investment income. Today, with shares trading at levels that reflect about a 350% climb from those pandemic bottoms, the company looks poised for more growth, though insider selling and some balance sheet quirks warrant a closer look. Let’s break down the fundamentals, trends, and what analysts see ahead in plain terms.
Revenue and Operational Resilience
EQH’s revenue tells a story of volatility but underlying strength, typical for an insurer where premiums, investment returns, and policy lapses drive the top line. From $11.8 billion in 2016, it dipped to $9.6 billion in 2019 (-18% drop) amid market pressures, then cratered to $7.6 billion in 2021 (-39% from 2020’s $12.4 billion) as pandemic fears hit annuity sales. But rebound time: 2022 surged to $12.6 billion (+66%), 2023 eased to $10.5 billion (-17%), and 2024 hit $12.4 billion (+18%). Analysts forecast a massive jump to $16.5 billion in 2025 (+33%) and $17.7 billion in 2026 (+7%), signaling optimism around higher rates boosting investment spreads and perhaps new product launches.
Revenue per employee, a gauge of efficiency, echoes this: peaking at $1.57 million in 2020 before settling around $1.55 million in 2024 despite staff hovering at 8,000. Fewer shares outstanding—down from 561 million in 2016 to just 283 million projected for 2026 (-50% total reduction)—supercharges per-share metrics. Revenue per share leaped from $18.24 in 2021 to $38.72 in 2024 (+112%), and predictions show $58.19 in 2026 (+50%). This share shrinkage, often from buybacks, amplifies returns for investors, making EQH more shareholder-friendly as earnings flow to fewer hands.
Gross margins have stabilized around 55-59% recently (up from 28% in 2019), reflecting better pricing power in a high-rate world. Why care? Margins show how well EQH controls costs on its core insurance and asset management ops—key in an industry where claims and lapses can swing wildly.
Profitability: From Losses to High ROE
Earnings paint the most dramatic picture. Net income swung from profits of $2.2 billion in 2018 to losses of $1.5 billion in 2019 (-170%) and $349 million in 2020, blamed on investment hits and reserves. Boom years followed: $2.17 billion in 2021 (+722% turnaround), $2.39 billion in 2022 (+10%), then $1.64 billion in 2023 (-31%) and a projected $1.82 billion in 2024 (+11%). Forecasts dip oddly to zero in 2025 (possibly conservative modeling) before climbing to $1.85 billion in 2026 (+huge rebound) and $1.98 billion in 2027 (+7%).
EPS tracks suit: $4.52 in 2022, down 23% to $3.49 in 2023, up 9% to $3.82 in 2024, with analysts eyeing $5.76 in 2026 (+51%) and $7.48 in 2027 (+30%). EBT margins hit 34% in 2021 but moderated to 17% in 2024—still robust, indicating solid pre-tax profitability from spreads on policyholder funds.
ROE, a star metric for shareholders (it measures bang-for-buck on equity), exploded to 32% in 2022, 55% in 2023, and 52% in 2024—way above the industry norm of 10-15%. This correlates tightly with shrinking equity base (from $17.2 billion in 2020 to $1.5 billion projected 2025, -91%) and fatter earnings, but watch for sustainability as book value per share tanks from $12.53 in 2023 to $4.92 in 2025 (-61%). ROIC at 60% in 2024 screams efficient capital use, tying back to EQH’s partial ownership in AllianceBernstein, which juices returns without heavy capex.
Cash Flow Turnaround and Balance Sheet Health
Cash flows were a sore spot—negative operating cash flow through 2023, with free cash flow per share mired at -$0.93. Then 2024 magic: Op CF $2.01 billion, FCF $1.85 billion, and FCF/share $5.77. This +1,300% FCF swing per share versus 2023’s negative aligns with higher rates lifting investment income, crucial for insurers who live off float like Berkshire Hathaway.
Debt’s up steadily (2.4 billion in 2017 to 6.6 billion projected 2025, +173%), but net debt swings from positive to -$5.9 billion (cash-rich). EV/FCF flips positive at 7.8x in 2024 from negative infinity—valuations now make sense. PS ratios hover 1.1-1.2x, cheap for growth; PB spiked to 34x in 2025 projection due to book value drop, flagging potential accounting noise from reserves.
Working capital’s massively negative (-$121 billion in 2024), normal for insurers holding policy liabilities, but it grew 16% worse YoY—monitor for reserve adequacy amid rate volatility.
Stock price evolution mirrors this: 2018 lows ~$15 amid spin-off hype, 2020 crash to $10 (-37%), recovery to $37 highs in 2022 (+270%), pullback to $22 lows in 2023 (-41%), then 2024 highs ~$51 (+132%). Recent close implies the stock’s up ~140% from 2023 lows, tracking EPS recovery and ROE surge, but lagging revenue predictions slightly.
Insider Activity: All Sells, No Buys
Here’s a yellow flag: Zero insider buys across 12 months to Feb 2026, but heavy selling totaling ~$32 million. CEO leads with routine monthly-ish blocks (30k-40k shares, e.g., 39,700 in Aug 2025 at high prices), COO dumping 6k-7k shares regularly, plus CFO, directors, and others. March 2025 saw 3 sells; May peaked at 7. Volumes suggest planned 10b5-1 sales (pre-scheduled to avoid timing issues), not panic dumping—common at profitable firms. Still, no buys amid 50%+ EPS growth forecasts? It tempers enthusiasm, as insiders aren’t loading up.
Valuation Metrics and Stock Price Momentum
PE ratios expanded from 6.5x in 2022 to 12.2x in 2024, reasonable for forecasted EPS doubling. PS steady ~1.1x, EV/Sales dipping to 1.2x. Compared to peers, EQH trades at a discount to growth potential, especially with FCF now positive.
Price targets scream upside: average implies ~35% gain from recent levels, low end ~28%, high ~55%. This consensus builds on revenue acceleration and EPS ramps, pricing in sustained high ROE but discounting near-term book value wobbles.
Looking Ahead: Growth Catalysts and Risks
Analysts bet on 2025-2027 tailwinds: Revenue +50% cumulative, EPS +100% from 2024, driven by rate hikes (boosting annuity spreads), EQH’s 2023 AllianceBernstein alliance deepening asset management fees, and buybacks shrinking shares further. Post-COVID, EQH’s focus on retirement products positions it for aging demographics. ROA/ROE staying north of 0.4%/50% would be elite.
Risks loom: Insurance is cyclical—rate cuts could squeeze margins (gross fell to 39% projected 2025). 2025 net income blank could signal one-offs. Ballooning debt (+10% YoY) and insider sells bear watching. Geopolitics or recessions hit investments hard, as in 2020.
Bottom line for retail investors: EQH’s transformed from loss-maker to cash cow, with stock rewarding patient holders (5x from IPO lows). At ~35% upside to consensus, it’s a buy for growth chasers tolerant of volatility—but diversify, as insurer betas amplify markets. Track Q1 2026 earnings for FCF confirmation.
(Word count: 1,128)